Switch theme
Sign up to access all valuation multiples
Implanet SA designs produce and sell medical implants and devices used in orthopedic surgery. Its products include prosthetic knees, spinal bracing systems, intersomatic cages, pins, suture threads, screws, and anchors. The company operates in a single segment - the commercialization of orthopedic implants. It derives Majority of its geographical revenue from France.
2007
46
LTM Revenue n/a
LTM EBITDA n/a
$17.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Implanet has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Implanet achieved revenue of $8.0M and an EBITDA of -$6.3M.
Implanet expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Implanet valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $8.6M | $8.0M | XXX | XXX | XXX |
| Gross Profit | $4.0M | $5.3M | XXX | XXX | XXX |
| Gross Margin | 46% | 67% | XXX | XXX | XXX |
| EBITDA | -$2.6M | -$6.3M | XXX | XXX | XXX |
| EBITDA Margin | -31% | -78% | XXX | XXX | XXX |
| Net Profit | -$4.9M | -$3.8M | XXX | XXX | XXX |
| Net Margin | -57% | -48% | XXX | XXX | XXX |
| Net Debt | $7.2M | $5.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Implanet's stock price is EUR 0 (or $0).
Implanet has current market cap of EUR 12.5M (or $13.5M), and EV of EUR 16.0M (or $17.2M).
See Implanet trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17.2M | $13.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Implanet has market cap of $13.5M and EV of $17.2M.
Implanet's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Implanet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Implanet and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $17.2M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | XXX | XXX |
| P/E | -1.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -7.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpImplanet's NTM/LTM revenue growth is n/a
Implanet's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Implanet's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Implanet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Implanet and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -78% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 137% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 25% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 115% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Implanet acquired XXX companies to date.
Last acquisition by Implanet was XXXXXXXX, XXXXX XXXXX XXXXXX . Implanet acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Implanet founded? | Implanet was founded in 2007. |
| Where is Implanet headquartered? | Implanet is headquartered in France. |
| How many employees does Implanet have? | As of today, Implanet has 46 employees. |
| Is Implanet publicy listed? | Yes, Implanet is a public company listed on PAR. |
| What is the stock symbol of Implanet? | Implanet trades under ALIMP ticker. |
| When did Implanet go public? | Implanet went public in 2013. |
| Who are competitors of Implanet? | Similar companies to Implanet include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Implanet? | Implanet's current market cap is $13.5M |
| What is the current revenue growth of Implanet? | Implanet revenue growth between 2023 and 2024 was -7%. |
| Is Implanet profitable? | Yes, Implanet is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
